Skip to content
Triangle logo TriangleGet started
← Acute Myeloid Leukemia

HEALTH PROFESSIONAL · SOURCE READING

Hypomethylating agents

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Refractory or Recurrent AML / Chemotherapy / Reduced-intensity therapy, including targeted therapy

Evidence (hypomethylating agents):

In a retrospective analysis, 655 patients with relapsed or primary treatment-refractory AML received either azacitidine (57%) or decitabine (43%).[21]

Source links and citations

In a retrospective analysis, 655 patients with relapsed or primary treatment-refractory AML received either azacitidine (57%) or decitabine (43%).[21]

Overall, 16% of patients achieved a CR or a CRi and experienced a median OS of 21 months.[21][Level of evidence C3]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice